Learning from large cardiovascular clinical trials: Classical cardiovascular risk factors

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The number of cardiovascular risk factors significantly influences age adjusted cardiovascular death rates according to the data of the MRFIT Trial. Up to 60% of patients with Type 2 diabetes have concomitant hypertension. In the HOT (Hypertension Optimal Treatment) Study lowering of blood pressure was particularly beneficial in the subgroup of diabetes mellitus: there was a 51% reduction in major cardiovascular events in target group ≤80 mmHg, compared with target group ≤90 mmHg (p = 0.005). Analysis of the diabetic patient group in the CAPPP (The CAPtopril Prevention Project) showed that captopril was superior for preventing cardiovascular events in hypertensive patients with diabetes. In the diabetic cohort of the LIFE Study losartan was more effective than athenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes and left ventricular hypertrophy. In the Heart Protection Study 5963 people with diabetes were studied. For the first occurrence of any major vascular events among diabetic participants, there was a 22% reduction in the event rate simvastatin-allocated versus placebo allocated patients (p <0.0001). DAIS (Diabetes Atherosclerosis Intervention Study) data suggest that treatment with fenofibrate reduces the angiographic progression of coronary artery disease in patients with Type 2 diabetes. According to results on multifactorial intervention in patients with Type 2 diabetes (the STENO-2 study) the overall cardiovascular risk reduction was 53%. In conclusion, management of cardiovascular risk factors should be considered as the cornerstone of diabetes care.

Original languageEnglish
JournalDiabetes Research and Clinical Practice
Volume68
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Clinical Trials
Learning
Type 2 Diabetes Mellitus
Captopril
Hypertension
Mortality
Fenofibrate
Simvastatin
Losartan
Left Ventricular Hypertrophy
Risk Reduction Behavior
Blood Vessels
Coronary Artery Disease
Atherosclerosis
Diabetes Mellitus
Cohort Studies
Placebos
Blood Pressure
Morbidity
Therapeutics

Keywords

  • Cardiovascular risk
  • Diabetes mellitus
  • Hyperlipidaemia
  • Hypertension
  • Smoking

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{526bef7c126c409cbad2bba644191848,
title = "Learning from large cardiovascular clinical trials: Classical cardiovascular risk factors",
abstract = "The number of cardiovascular risk factors significantly influences age adjusted cardiovascular death rates according to the data of the MRFIT Trial. Up to 60{\%} of patients with Type 2 diabetes have concomitant hypertension. In the HOT (Hypertension Optimal Treatment) Study lowering of blood pressure was particularly beneficial in the subgroup of diabetes mellitus: there was a 51{\%} reduction in major cardiovascular events in target group ≤80 mmHg, compared with target group ≤90 mmHg (p = 0.005). Analysis of the diabetic patient group in the CAPPP (The CAPtopril Prevention Project) showed that captopril was superior for preventing cardiovascular events in hypertensive patients with diabetes. In the diabetic cohort of the LIFE Study losartan was more effective than athenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes and left ventricular hypertrophy. In the Heart Protection Study 5963 people with diabetes were studied. For the first occurrence of any major vascular events among diabetic participants, there was a 22{\%} reduction in the event rate simvastatin-allocated versus placebo allocated patients (p <0.0001). DAIS (Diabetes Atherosclerosis Intervention Study) data suggest that treatment with fenofibrate reduces the angiographic progression of coronary artery disease in patients with Type 2 diabetes. According to results on multifactorial intervention in patients with Type 2 diabetes (the STENO-2 study) the overall cardiovascular risk reduction was 53{\%}. In conclusion, management of cardiovascular risk factors should be considered as the cornerstone of diabetes care.",
keywords = "Cardiovascular risk, Diabetes mellitus, Hyperlipidaemia, Hypertension, Smoking",
author = "P. Kempler",
year = "2005",
month = "6",
doi = "10.1016/j.diabres.2005.03.005",
language = "English",
volume = "68",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Learning from large cardiovascular clinical trials

T2 - Classical cardiovascular risk factors

AU - Kempler, P.

PY - 2005/6

Y1 - 2005/6

N2 - The number of cardiovascular risk factors significantly influences age adjusted cardiovascular death rates according to the data of the MRFIT Trial. Up to 60% of patients with Type 2 diabetes have concomitant hypertension. In the HOT (Hypertension Optimal Treatment) Study lowering of blood pressure was particularly beneficial in the subgroup of diabetes mellitus: there was a 51% reduction in major cardiovascular events in target group ≤80 mmHg, compared with target group ≤90 mmHg (p = 0.005). Analysis of the diabetic patient group in the CAPPP (The CAPtopril Prevention Project) showed that captopril was superior for preventing cardiovascular events in hypertensive patients with diabetes. In the diabetic cohort of the LIFE Study losartan was more effective than athenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes and left ventricular hypertrophy. In the Heart Protection Study 5963 people with diabetes were studied. For the first occurrence of any major vascular events among diabetic participants, there was a 22% reduction in the event rate simvastatin-allocated versus placebo allocated patients (p <0.0001). DAIS (Diabetes Atherosclerosis Intervention Study) data suggest that treatment with fenofibrate reduces the angiographic progression of coronary artery disease in patients with Type 2 diabetes. According to results on multifactorial intervention in patients with Type 2 diabetes (the STENO-2 study) the overall cardiovascular risk reduction was 53%. In conclusion, management of cardiovascular risk factors should be considered as the cornerstone of diabetes care.

AB - The number of cardiovascular risk factors significantly influences age adjusted cardiovascular death rates according to the data of the MRFIT Trial. Up to 60% of patients with Type 2 diabetes have concomitant hypertension. In the HOT (Hypertension Optimal Treatment) Study lowering of blood pressure was particularly beneficial in the subgroup of diabetes mellitus: there was a 51% reduction in major cardiovascular events in target group ≤80 mmHg, compared with target group ≤90 mmHg (p = 0.005). Analysis of the diabetic patient group in the CAPPP (The CAPtopril Prevention Project) showed that captopril was superior for preventing cardiovascular events in hypertensive patients with diabetes. In the diabetic cohort of the LIFE Study losartan was more effective than athenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes and left ventricular hypertrophy. In the Heart Protection Study 5963 people with diabetes were studied. For the first occurrence of any major vascular events among diabetic participants, there was a 22% reduction in the event rate simvastatin-allocated versus placebo allocated patients (p <0.0001). DAIS (Diabetes Atherosclerosis Intervention Study) data suggest that treatment with fenofibrate reduces the angiographic progression of coronary artery disease in patients with Type 2 diabetes. According to results on multifactorial intervention in patients with Type 2 diabetes (the STENO-2 study) the overall cardiovascular risk reduction was 53%. In conclusion, management of cardiovascular risk factors should be considered as the cornerstone of diabetes care.

KW - Cardiovascular risk

KW - Diabetes mellitus

KW - Hyperlipidaemia

KW - Hypertension

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=20444407302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444407302&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2005.03.005

DO - 10.1016/j.diabres.2005.03.005

M3 - Article

C2 - 15955374

AN - SCOPUS:20444407302

VL - 68

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - SUPPL. 1

ER -